BR0109499A - Tratamento melhorado de neovascularização - Google Patents

Tratamento melhorado de neovascularização

Info

Publication number
BR0109499A
BR0109499A BR0109499-8A BR0109499A BR0109499A BR 0109499 A BR0109499 A BR 0109499A BR 0109499 A BR0109499 A BR 0109499A BR 0109499 A BR0109499 A BR 0109499A
Authority
BR
Brazil
Prior art keywords
treatment
enhanced neovascularization
neovascularization treatment
enhanced
improved
Prior art date
Application number
BR0109499-8A
Other languages
English (en)
Inventor
Romulus Kimbro Brazzell
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0109499A publication Critical patent/BR0109499A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TRATAMENTO MELHORADO DE NEOVASCULARIZAçãO". A presente invenção refere-se a um tratamento fotodinâmico melhorado para tratar a neovascularização coroidal subfoveal (CNV).
BR0109499-8A 2000-03-24 2001-03-22 Tratamento melhorado de neovascularização BR0109499A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19180700P 2000-03-24 2000-03-24
PCT/EP2001/003265 WO2001074389A2 (en) 2000-03-24 2001-03-22 Improved treatment of neovascularization

Publications (1)

Publication Number Publication Date
BR0109499A true BR0109499A (pt) 2002-12-10

Family

ID=22707008

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109499-8A BR0109499A (pt) 2000-03-24 2001-03-22 Tratamento melhorado de neovascularização

Country Status (21)

Country Link
US (4) US20010039438A1 (pt)
EP (1) EP1265636A2 (pt)
JP (1) JP2003528926A (pt)
KR (2) KR20070114856A (pt)
CN (1) CN100398153C (pt)
AR (1) AR032151A1 (pt)
AU (2) AU2001250401B2 (pt)
BR (1) BR0109499A (pt)
CA (1) CA2403612A1 (pt)
CZ (1) CZ20023174A3 (pt)
EE (1) EE200200547A (pt)
HU (1) HUP0300347A3 (pt)
IL (1) IL151833A0 (pt)
MX (1) MXPA02009351A (pt)
NO (1) NO20024486D0 (pt)
NZ (1) NZ521360A (pt)
PL (1) PL359027A1 (pt)
RU (1) RU2271222C2 (pt)
UA (1) UA75350C2 (pt)
WO (1) WO2001074389A2 (pt)
ZA (1) ZA200207638B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032151A1 (es) * 2000-03-24 2003-10-29 Novartis Ag Uso de un farmaco anti-angiogenico en conjunto con un agente fotosensible para la preparacion de un medicamento para el tratamiento fotodinamico mejorado de la neovasculatura indeseada
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
EA006746B1 (ru) * 2001-11-09 2006-04-28 Айтек Фармасьютикалз Способы лечения глазных неоваскулярных заболеваний
JP2006501902A (ja) 2002-10-03 2006-01-19 ライト サイエンシズ コーポレイション 眼組織中の光感受性化合物を励起させるシステム及び方法
RU2358753C2 (ru) 2003-08-07 2009-06-20 Хилор Лтд. Фармацевтические композиции и способы для ускорения заживления ран
US20050043786A1 (en) * 2003-08-18 2005-02-24 Medtronic Ave, Inc. Methods and apparatus for treatment of aneurysmal tissue
FR2867189A1 (fr) * 2004-03-08 2005-09-09 Ludovic Bourre Nouveaux composes medicamenteux destines au traitement des pathologies dependantes de l'activite proteine kinase
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
WO2006015016A2 (en) * 2004-07-30 2006-02-09 Massachusetts Eye And Ear Infirmary Photodynamic therapy and compositions for treating ocular glaucoma
AU2006286152B2 (en) 2005-08-29 2012-05-31 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US8753673B2 (en) * 2006-05-23 2014-06-17 Taiwan Liposome Co. Ltd. Liposome composition for delivery of a therapeutic agent to eyes
CA2694927A1 (en) * 2007-07-30 2009-02-05 Healor Ltd. Compositions for wound healing comprising insulin and an alpha-pkc inhibitor and being free of calcium and magnesium ions
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
ES2468827T3 (es) 2010-01-14 2014-06-17 Sanwa Kagaku Kenkyusho Co., Ltd Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada
RU2449821C1 (ru) * 2010-09-01 2012-05-10 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "МНИОИ им. П.А.Герцена Минздравсоцразвития России") Способ модификации фотодинамического лечения

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
CA2087902C (en) * 1992-02-05 2006-10-17 Narendra Raghunathji Desai Liposome compositions of porphyrin photosensitizers
DE947222T1 (de) * 1992-11-20 2000-05-04 Univ British Columbia Verfahren zur Aktivierung von photoempfindlichen Mitteln
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5707608A (en) * 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
US6214819B1 (en) * 1998-11-23 2001-04-10 Novartis Ag Method for treating ocular neovascular diseases
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
US6271233B1 (en) * 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
CA2395567A1 (en) * 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
CA2714081C (en) * 2000-02-10 2013-08-06 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
AR032151A1 (es) * 2000-03-24 2003-10-29 Novartis Ag Uso de un farmaco anti-angiogenico en conjunto con un agente fotosensible para la preparacion de un medicamento para el tratamiento fotodinamico mejorado de la neovasculatura indeseada

Also Published As

Publication number Publication date
JP2003528926A (ja) 2003-09-30
AU2001250401B2 (en) 2005-08-11
US20060263392A1 (en) 2006-11-23
NO20024486L (no) 2002-09-19
CA2403612A1 (en) 2001-10-11
AU5040101A (en) 2001-10-15
KR20070114856A (ko) 2007-12-04
HUP0300347A2 (hu) 2003-06-28
AR032151A1 (es) 2003-10-29
CN100398153C (zh) 2008-07-02
IL151833A0 (en) 2003-04-10
ZA200207638B (en) 2003-10-16
PL359027A1 (en) 2004-08-23
CZ20023174A3 (cs) 2003-01-15
US20120203162A1 (en) 2012-08-09
RU2271222C2 (ru) 2006-03-10
UA75350C2 (en) 2006-04-17
US20080096865A1 (en) 2008-04-24
CN1420788A (zh) 2003-05-28
NZ521360A (en) 2004-07-30
WO2001074389A3 (en) 2002-07-11
US8158669B2 (en) 2012-04-17
NO20024486D0 (no) 2002-09-19
KR20020082487A (ko) 2002-10-31
HUP0300347A3 (en) 2005-03-29
WO2001074389A2 (en) 2001-10-11
US8862224B2 (en) 2014-10-14
MXPA02009351A (es) 2003-02-12
US20010039438A1 (en) 2001-11-08
EP1265636A2 (en) 2002-12-18
EE200200547A (et) 2004-02-16

Similar Documents

Publication Publication Date Title
BR0109499A (pt) Tratamento melhorado de neovascularização
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
DK0841949T3 (da) Anvendelse af saccharid-konjugater
ECSP045098A (es) Procedimientos para tratar enfermedades neovasculares oculares
AU3056702A (en) Methods and compositions for treatment of ocular neovascularization and neural injury
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
MY119375A (en) Treatment of tinnitus using neuroprotective agents
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
EA200501251A1 (ru) Антинеопластические комбинации
AU3831301A (en) Method for treating ocular pain
ATE397458T1 (de) Neue heilmittel für krebs
TR199901104T2 (xx) Farmas�tik bile�ikler.
DK1695714T3 (da) Genetisk manipuleret herpesvirus til behandling af tumorer
ID29970A (id) Metode untuk mengobati penyakit neovaskuler okuler
ATE407923T1 (de) Tyrosinderivate als phosphatase inhibitoren
PT1126853E (pt) Distribuicao controlada de anti-depressivos
EP1570859A3 (en) Improved treatment of neovascularization
BR0210678A (pt) Carbamatos de 2-heterocìclicos-1,2-etanodióis
ES2171838T3 (es) Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para el tratamiento del trastorno bipolar.
DK0750502T3 (da) Anvendelse af phosphorderivater af alkaloider til behandling af endokrinopatier
ECSP003455A (es) Derivados monofluoroalquilo

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.